HK inno.N announced on the 11th that its operating profit on a separate basis was 88.2 billion won, which is a 33.8% increase compared to the previous year.
During the same period, revenue was 897.1 billion won, up 8.2% from the previous year, and net income also grew by 30.5% to 61.6 billion won.
The strong performance was largely attributed to the increase in sales of the company’s main product, the gastroesophageal reflux disease treatment "K-Cap" (ingredient name: Tegoprazan). K-Cap’s sales last year were 168.8 billion won, a 41.2% increase from 119.5 billion won the previous year.
HK inno.N recorded sales of 235.8 billion won, operating profit of 24.4 billion won, and net income of 19.2 billion won in the fourth quarter of last year.